Clinical Trial Update: Evaluating Safety and Efficacy of FID 112903 Post Discontinuation of Long-term Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% [Phase 4]

View source ↗

Summary

Phase 4 clinical trial has completed, evaluating the safety and efficacy of FID 112903 after discontinuation of long-term RESTASIS (cyclosporine ophthalmic emul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Syndrome

Drugs mentioned

• FID 112903
• Restasis (Cyclosporine A)

Snippet

Sponsor: Alcon Research | Conditions: Dry Eye Syndrome | Phase 4 | Status: COMPLETED